Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06243718 · ClinicalTrials.gov registry record
Phrenic Nerve Reconstruction for the Treatment of Diaphragmatic Paralysis: Patient Experiences and Reported Outcomes.
A clinical trial of Breath Shortness and Diaphragmatic Paralysis, sponsored by Advanced Reconstructive Surgery Alliance.
- Recruiting
- Registry status
- 45
- Enrollment target
- 2
- Study locations
NCT06243718: Recruiting study of Breath Shortness and Diaphragmatic Paralysis, sponsored by Advanced Reconstructive Surgery Alliance.
NCT06243718 is a study of Breath Shortness and Diaphragmatic Paralysis that is actively recruiting participants, run by Advanced Reconstructive Surgery Alliance. The registered enrollment target is 45 participants. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06243718, a study of Breath Shortness and Diaphragmatic Paralysis, is actively recruiting participants, sponsored by Advanced Reconstructive Surgery Alliance.
- RECRUITING
- Registry status
- 45 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study utilizes a grounded theory methodology to explore patient experiences of phrenic nerve reconstructive surgery as a treatment for diaphragmatic paralysis.
Primary Outcome
The interviews will serve a dual purpose: first, to delve into the daily experiences of individuals living with diaphragmatic paralysis, aiming to uncover the practical and emotional realities they face; and second, to explore the experiences and perceived outcomes of phrenic nerve surgery as a treatment for diaphragmatic paralysis.
Conditions Studied
Study Locations (2)
New Jersey
- Advanced Reconstructive Surgery Alliance - Red Bank
- Institute for Advanced Reconstruction - Shrewsbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-10-10 |
| Est. Completion | 2026-10-10 |
What NCT06243718 shows while recruiting
NCT06243718 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 3 conditions, with Breath Shortness appearing as the primary indexed condition, and to 0 interventions.
NCT06243718 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06243718 about?
NCT06243718 is a clinical study titled "Phrenic Nerve Reconstruction for the Treatment of Diaphragmatic Paralysis: Patient Experiences and Reported Outcomes.". This study utilizes a grounded theory methodology to explore patient experiences of phrenic nerve reconstructive surgery as a treatment for diaphragmatic paralysis.
What is the current status of trial NCT06243718?
This trial is currently recruiting. The enrollment target is 45 participants. The study started on 2023-10-10. Estimated completion is 2026-10-10.
What conditions does trial NCT06243718 study?
This clinical trial studies the following conditions: Breath Shortness, Diaphragmatic Paralysis, Pain, Chest.
Who is sponsoring clinical trial NCT06243718?
This trial is sponsored by Advanced Reconstructive Surgery Alliance, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06243718 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breath Shortness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI